Real Peptides 101 Guide

Ask where the peptide is synthesized and whether purity is verified post-production through independent HPLC. If the supplier can't name the manufacturing facility or provide third-party test results, the cost difference reflects missing quality controls. Not competitive pricing. A peptide at 92% purity costs half what a 99% purity peptide costs because the synthesis process was rushed, sterility testing was skipped, and no post-production verification occurred. That 50% savings becomes a 100% loss when the experiment fails due to contamination or sequence errors.

Send a sample to an independent analytical lab for HPLC and mass spectrometry testing. Universities with biochemistry departments often offer this as a fee-for-service. Request both purity determination (HPLC) and molecular weight confirmation (mass spec). If the independent result differs from the supplier's COA by more than 2%, the supplier's quality control process is unreliable. This is expensive (typically $300–600 per test), but it's the only way to verify supplier claims when reproducibility is critical.

A COA showing purity below 95% for a thymic peptide indicates either synthesis error or post-synthesis degradation. Request a replacement batch with a current COA. Reputable suppliers will retest and reship. If the supplier refuses or provides only supplier-generated documentation, the product likely doesn't meet research-grade standards. Our team has seen labs waste months troubleshooting protocols before realizing the peptide itself was the variable.

Discard the vial immediately and contact the supplier for replacement. Visible particulates indicate either aggregation during lyophilisation (caused by rapid freeze-drying or high residual moisture) or contamination introduced during filling. Aggregated peptides have reduced bioavailability because receptor binding requires monomeric structure. Aggregates don't dissociate fully in solution. Real Peptides guarantees particle-free reconstitution; if particulates appear, the batch failed quality control and should not have shipped.

Prioritize verification depth over volume pricing for experiments where reproducibility is critical, and consider cost-efficient suppliers for preliminary screening studies. A 30% cost saving means nothing if experimental failure requires repeating an entire study due to inconsistent peptide batches. For dose-response studies, receptor binding assays, or pharmacokinetic analyses where precision matters, invest in verified peptides. For preliminary viability screening or protocol optimization where approximate activity is sufficient, lower-cost suppliers may be acceptable. The real peptides vs amino asylum decision becomes context-dependent: high-stakes experiments justify premium suppliers, while exploratory work tolerates higher variability risk.